(Q34294786)

1 August 2017

1 reference

title

The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies (English)

1 reference

1 August 2017

1 reference

Rubin RH

1

1 reference

1 August 2017

Ikonen T

series ordinal

2

1 reference

1 August 2017

Gummert JF

series ordinal

3

1 reference

1 August 2017

Morris RE

series ordinal

4

1 reference

1 August 2017

language of work or name

1 reference

1 March 1999

1 reference

Transplant Infectious Disease

1 August 2017

published in

1 reference

1 August 2017

volume

1

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

29-39

1 reference

Infection in organ-transplant recipients

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Effects of Gamma‐Interferon and FK506 on Resting B Cell Proliferation of New Zealand Black/White F1 Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Effects of rapamycin on cultured hepatocyte proliferation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Rapamycin inhibits vascular smooth muscle cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Mechanism of action of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Antimicrobial strategies in the care of organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

The Rapamycin and FKBP12 Target (RAFT) Displays Phosphatidylinositol 4-Kinase Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Monitoring of cyclosporin and azathioprine in organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Azathioprine treatment and thiopurine metabolism in rheumatic diseases. Introduction and first results of investigation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

The mechanism of action of FK-506 and cyclosporin A.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Long-term in vivo effects of rapamycin on humoral and cellular immune responses in the rat

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.10104.X

7 January 2021

10.1034/J.1399-3062.1999.10104.X

Identifiers

DOI

1 reference

1 August 2017

1 reference